Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy

被引:88
作者
Ferrari, S
Bacci, G
Picci, P
Mercuri, M
Briccoli, A
Pinto, D
Gasbarrini, A
Tienghi, A
delPrever, AB
机构
[1] DIV MED ONCOL, RAVENNA, ITALY
[2] UNIV TURIN, DEPT PAEDIAT, TURIN, ITALY
关键词
high-dose methotrexate; lactic dehydrogenase; metastasectomy; neoadjuvant chemotherapy; non-metastatic osteosarcoma of the extremity; tumor necrosis;
D O I
10.1023/A:1008221713505
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Most of the studies of the treatment of nonmetastatic osteosarcoma of the extremity have reported results in terms of probability of survival up to five years with a minimum follow-up of less than two to three years. Definition of reliable indicators of prognosis and predictive factors for survival require mature data derived from a long-term survival analysis. Patients and methods: A review of 127 patients with nonmetastatic osteosarcoma of the extremity, treated between March 1983 and June 1986, was performed. The treatment protocol consisted of primary chemotherapy with MTX (randomization to high vs. moderate dosages) and CDP followed by surgery. Postoperatively, patients with < 60% tumor necrosis received ADM and BCD; those with tumor necrosis greater than or equal to 60% < 90% (Fair Responders FR) were given MTX, CDP and ADM. Up to January 1984, patients with tumor necrosis > 90% received MTX and CDP only, and after then they were given the same treatment as for FR. A multivariate analysis to test predictive factors for survival was performed. Results. With a median follow-up of 134 months (range 114-153), the 12-year DFS was 46%. A good histologic response, an LDH baseline value within the normal range, and the use of high-dose MTX were positive predictive factors for DFS. With a median time of observation for survivors of 130 months, the 12-year overall survival was 53%. None of the patients who relapsed with local or distant recurrences other than lung metastasis are now alive. Patients with a relapse-free interval longer than 24 months had a significantly better post-relapse survival than those with a shorter relapse-free interval (40% vs. 7%; P = 0.0159). All of the patients who were not surgically treated had disease progression and died within 40 months after the first recurrence. The surgically-treated patients had a 30% post-relapse survival probability. Conclusions: In non-metastatic osteosarcoma of the extremity, chemotherapy-induced tumor necrosis, the baseline LDH serum value and the use of HDMTX are significant predictive factors for DFS. The relapse-free interval and the possibility of metastasectomy are significant factors conditioning the post-relapse survival.
引用
收藏
页码:765 / 771
页数:7
相关论文
共 47 条
[1]  
BACCI G, 1993, CANCER-AM CANCER SOC, V71, P1224, DOI 10.1002/1097-0142(19930215)71:4<1224::AID-CNCR2820710409>3.0.CO
[2]  
2-M
[3]   Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs [J].
Bacci, G ;
Ferrari, S ;
Picci, P ;
Zolezzi, C ;
Gherlinzoni, F ;
Iantorno, D ;
Cazzola, A .
JOURNAL OF CHEMOTHERAPY, 1996, 8 (06) :472-478
[4]  
BACCI G, 1990, CANCER, V65, P2539, DOI 10.1002/1097-0142(19900601)65:11<2539::AID-CNCR2820651125>3.0.CO
[5]  
2-M
[6]  
BENJAMIN RS, 1995, P AN M AM SOC CLIN, V14, P516
[7]  
BERON G, 1988, CONTR ONCOL, V30, P143
[8]   Tumor size and prognosis in aggressively treated osteosarcoma [J].
Bieling, P ;
Rehan, N ;
Winkler, P ;
Helmke, K ;
Maas, R ;
Fuchs, N ;
Bielack, S ;
Heise, U ;
Jurgens, H ;
Treuner, J ;
Romanowski, R ;
Exner, U ;
Kotz, R ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :848-858
[9]   A COMPARISON OF 2 SHORT INTENSIVE ADJUVANT CHEMOTHERAPY REGIMENS IN OPERABLE OSTEOSARCOMA OF LIMBS IN CHILDREN AND YOUNG-ADULTS - THE 1ST STUDY OF THE EUROPEAN OSTEOSARCOMA INTERGROUP [J].
BRAMWELL, VHC ;
BURGERS, M ;
SNEATH, R ;
SOUHAMI, R ;
VANOOSTEROM, AT ;
VOUTE, PA ;
ROUESSE, J ;
SPOONER, D ;
CRAFT, AW ;
SOMERS, R ;
PRINGLE, J ;
MALCOLM, AJ ;
VANDEREIJKEN, J ;
THOMAS, D ;
USCINSKA, B ;
MACHIN, D ;
VANGLABBEKE, M .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (10) :1579-1591
[10]  
CAMPANACCI M, 1981, CANCER, V48, P1569, DOI 10.1002/1097-0142(19811001)48:7<1569::AID-CNCR2820480717>3.0.CO